z-logo
open-access-imgOpen Access
Type III interferons disrupt the lung epithelial barrier upon viral recognition
Author(s) -
Achille Broggi,
Sreya Ghosh,
Benedetta Sposito,
Roberto Spreafico,
Fabio Balzarini,
Antonino Lo Cascio,
Nicola Clementi,
Maria De Santis,
Nicasio Mancini,
Francesca Granucci,
Ivan Zai
Publication year - 2020
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.abc3545
Subject(s) - proinflammatory cytokine , immunology , interferon , biology , immune system , lung , tumor necrosis factor alpha , inflammation , interferon type i , virology , medicine
Viral infections of the lower respiratory tract are a leading cause of mortality. Mounting evidence indicates that most severe cases are characterized by aberrant immune responses and do not depend on viral burden. In this study, we assessed how type III interferons (IFN-λ) contribute to the pathogenesis induced by RNA viruses. We report that IFN-λ is present in the lower, but not upper, airways of patients with coronavirus disease 2019 (COVID-19). In mice, we demonstrate that IFN-λ produced by lung dendritic cells in response to a synthetic viral RNA induces barrier damage, causing susceptibility to lethal bacterial superinfections. These findings provide a strong rationale for rethinking the pathophysiological role of IFN-λ and its possible use in clinical practice against endemic viruses, such as influenza virus as well as the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom